|
WO2007062676A1
(en)
|
2005-12-01 |
2007-06-07 |
B.R.A.H.M.S. Aktiengesellschaft |
Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
|
|
AU2007237096C1
(en)
|
2006-04-07 |
2012-12-13 |
EyePoint Pharmaceuticals, Inc. |
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
|
|
AU2014243418B2
(en)
*
|
2010-04-30 |
2016-09-22 |
Molecular Partners Ag |
Modified binding proteins inhibiting the VEGF-A receptor interaction
|
|
TWI510246B
(zh)
*
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
KR101782790B1
(ko)
*
|
2010-11-26 |
2017-09-28 |
몰리큘라 파트너스 아게 |
혈청 알부민에 결합하는 설계된 반복 단백질
|
|
KR20140039203A
(ko)
|
2011-04-29 |
2014-04-01 |
얀센 바이오테크 인코포레이티드 |
Il4/il13 결합 반복 단백질 및 용도
|
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
|
US20130095065A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for Treating Vascular Leak Syndrome and Cancer
|
|
EP2780370B1
(en)
|
2011-11-16 |
2019-09-25 |
AdrenoMed AG |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
|
|
SG10201802054TA
(en)
|
2011-11-16 |
2018-05-30 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
|
|
SG11201402362VA
(en)
|
2011-11-16 |
2014-06-27 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
|
|
PT2594588E
(pt)
|
2011-11-16 |
2014-08-28 |
Adrenomed Ag |
Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para utilização em terapia
|
|
HUE032648T2
(en)
|
2011-11-16 |
2017-10-30 |
Sphingotec Gmbh |
Adrenomedullin assays and procedures for determining the concentration of mature adrenomedullin
|
|
PT3553084T
(pt)
|
2011-11-16 |
2023-02-17 |
Adrenomed Ag |
Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda
|
|
CN103308670B
(zh)
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
|
CN103308673B
(zh)
|
2012-03-08 |
2017-05-31 |
思芬构技术有限公司 |
用于预测雌性对象中发生心血管事件的风险的方法
|
|
CN103308689B
(zh)
|
2012-03-08 |
2017-04-12 |
思芬构技术有限公司 |
用于预测雌性对象中患上癌症的风险或诊断癌症的方法
|
|
US10568934B2
(en)
*
|
2012-05-07 |
2020-02-25 |
Allergan, Inc. |
Method of treating AMD in patients refractory to anti-VEGF therapy
|
|
LT3679922T
(lt)
|
2012-06-01 |
2021-10-25 |
Novartis Ag |
Švirkštas
|
|
KR20150023957A
(ko)
*
|
2012-06-28 |
2015-03-05 |
몰리큘라 파트너스 아게 |
혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
|
|
JOP20200175A1
(ar)
|
2012-07-03 |
2017-06-16 |
Novartis Ag |
حقنة
|
|
AU2013100070B4
(en)
*
|
2012-07-03 |
2013-04-04 |
Novartis Ag |
Use of device
|
|
AU2012101677B4
(en)
|
2012-07-03 |
2012-12-20 |
Novartis Ag |
Device
|
|
US20150297675A1
(en)
*
|
2012-08-28 |
2015-10-22 |
Aaron Osborne |
Use of a vegf antagonist in treating ocular vascular proliferative diseases
|
|
DK2904403T3
(en)
|
2012-10-02 |
2018-07-16 |
Sphingotec Gmbh |
PROCEDURE FOR DIAGNOSTICATION OR MONITORING OF Kidney Function or Diagnosis of Kidney Function
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
US20150346222A1
(en)
|
2013-01-08 |
2015-12-03 |
Sphingotec Gmbh |
Fasting levels of growth hormone as a predictive marker of cardiovascular risk
|
|
EP3444278A1
(en)
*
|
2013-02-26 |
2019-02-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
WO2014151725A1
(en)
*
|
2013-03-14 |
2014-09-25 |
Allergan, Inc. |
Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
|
|
US10598674B2
(en)
|
2013-03-20 |
2020-03-24 |
Sphingotec Gmbh |
Adrenomedullin to guide therapy of blood pressure decline
|
|
FR3004650B1
(fr)
*
|
2013-04-22 |
2015-05-29 |
Affilogic |
Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
|
|
CN105209483B
(zh)
|
2013-05-31 |
2021-07-27 |
分子组合公司 |
与肝细胞生长因子结合的设计锚蛋白重复蛋白
|
|
JP2016522249A
(ja)
|
2013-06-20 |
2016-07-28 |
ノバルティス アーゲー |
脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
|
|
EP3010542A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Treatment of polypoidal choroidal vasculopathy
|
|
EP3010526A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating macular edema
|
|
US20160168240A1
(en)
*
|
2013-07-11 |
2016-06-16 |
Sergey AKSENOV |
Use of vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
RU2676303C2
(ru)
*
|
2013-07-11 |
2018-12-27 |
Новартис Аг |
Использование антагониста vegf для лечения ретролентальной фиброплазии
|
|
EP3019243A4
(en)
|
2013-07-12 |
2017-03-15 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological conditions
|
|
PT3065761T
(pt)
*
|
2013-11-05 |
2020-02-21 |
Allergan Inc |
Método de tratamento de condições oculares com um darpin anti-vegf
|
|
EP3492495A1
(en)
|
2014-05-12 |
2019-06-05 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
|
EP3002589A1
(en)
|
2014-10-01 |
2016-04-06 |
sphingotec GmbH |
A method for stratifying a female subject for hormone replacement therapy
|
|
SG11201707606RA
(en)
*
|
2015-04-02 |
2017-10-30 |
Molecular Partners Ag |
Designed ankyrin repeat domains with binding specificity for serum albumin
|
|
JP6841765B2
(ja)
|
2015-04-24 |
2021-03-10 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
慢性腎疾患の発症のリスクを予測するための方法
|
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
|
CA3005132A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Coated syringe for ophthalmic formulations containing a vegf antagonist
|
|
WO2017085253A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
RU2734958C2
(ru)
|
2015-11-18 |
2020-10-26 |
Формикон Аг |
Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
|
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
CN115951066A
(zh)
|
2016-02-29 |
2023-04-11 |
麦恩泰科特有限公司 |
可用于治疗湿性年龄相关性黄斑变性的预测性标志物
|
|
EP3854817A1
(en)
|
2016-04-21 |
2021-07-28 |
4TEEN4 Pharmaceuticals GmbH |
Methods for determining dpp3 and therapeutic methods
|
|
MA45493A
(fr)
|
2016-06-27 |
2019-05-01 |
Aicuris Anti Infective Cures Gmbh |
Inhibiteurs d'entrée de hcmv.
|
|
EP3482208B1
(en)
|
2016-07-08 |
2023-04-12 |
SphingoTec GmbH |
Adrenomedullin for assessing congestion in a subject with acute heart failure
|
|
AU2017299581B2
(en)
|
2016-07-20 |
2024-05-23 |
EyePoint Pharmaceuticals, Inc. |
Humanized monoclonal antibodies that target ve-ptp (hptp-β)
|
|
NZ751689A
(en)
|
2016-09-22 |
2021-07-30 |
Molecular Partners Ag |
Recombinant binding proteins and their use
|
|
EP3309550A1
(en)
|
2016-10-12 |
2018-04-18 |
sphingotec GmbH |
Method for the detection of apolipoprotein e4
|
|
MX2019007107A
(es)
|
2016-12-16 |
2019-10-21 |
Adrenomed Ag |
Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
|
|
EP3339324A1
(en)
|
2016-12-22 |
2018-06-27 |
sphingotec GmbH |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
|
CA3063995A1
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
EP3630043A1
(en)
|
2017-05-24 |
2020-04-08 |
Formycon AG |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
CA3065415A1
(en)
|
2017-05-30 |
2018-12-06 |
Sphingotec Gmbh |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
BR112020003377A2
(pt)
|
2017-08-18 |
2020-08-25 |
Cambridge Enterprise Limited |
proteínas de ligação modulares
|
|
CA3076691A1
(en)
|
2017-09-25 |
2019-03-28 |
Adrenomed Ag |
Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
|
|
EP3698134A1
(en)
|
2017-10-18 |
2020-08-26 |
AdrenoMed AG |
Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
|
|
AU2018356370A1
(en)
|
2017-10-24 |
2020-04-09 |
Sphingotec Gmbh |
Selenoprotein P for prediction of a first cardiovascular event
|
|
CN111542548B
(zh)
|
2017-10-25 |
2024-07-30 |
4Teen4制药有限公司 |
针对并结合于特异性dpp3表位的dpp3结合剂及其在预防或治疗与氧化应激相关的疾病/急性病状中的用途
|
|
AU2019219071A1
(en)
|
2018-02-08 |
2020-07-30 |
Sphingotec Gmbh |
Adrenomedullin (ADM) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
|
|
EP3569614A1
(en)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
|
|
EP3586865A1
(en)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
|
|
JP7695187B2
(ja)
|
2018-09-24 |
2025-06-18 |
アイポイント ファーマシューティカルズ， インコーポレイテッド |
ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
|
|
AU2019408553A1
(en)
|
2018-12-20 |
2021-06-17 |
Sphingotec Gmbh |
Selenoprotein P in heart failure
|
|
US20220211798A1
(en)
|
2018-12-21 |
2022-07-07 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
|
|
US20200385488A1
(en)
|
2019-06-04 |
2020-12-10 |
Molecular Partners Ag |
Multispecific proteins
|
|
EP4014049A1
(en)
|
2019-08-15 |
2022-06-22 |
sphingotec GmbH |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
|
|
CN114556100A
(zh)
|
2019-08-30 |
2022-05-27 |
4Teen4制药有限公司 |
用于治疗休克的疗法指引和/或疗法监测
|
|
IL293698A
(en)
|
2019-12-11 |
2022-08-01 |
Molecular Partners Ag |
Recombinant peptide-mhc complex binding proteins, their production and use
|
|
EP3871689A1
(en)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
|
|
WO2021170880A2
(en)
|
2020-02-27 |
2021-09-02 |
Adrenomed Ag |
Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
|
|
BR112022015215A2
(pt)
|
2020-02-27 |
2022-10-11 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 para orientação, monitoramento e estratificação de terapia de anticorpos nt-adm em pacientes com choque
|
|
JP2023515042A
(ja)
|
2020-02-27 |
2023-04-12 |
アドレノメト アクチェンゲゼルシャフト |
ショックの治療若しくは予防において使用するための抗アドレノメデュリン（ＡＤＭ）抗体若しくは抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
|
|
EP3922993A1
(en)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
US20210285949A1
(en)
|
2020-03-16 |
2021-09-16 |
Sphingotec Gmbh |
Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
|
|
US20230213519A1
(en)
|
2020-03-16 |
2023-07-06 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
AU2021267411A1
(en)
|
2020-05-06 |
2022-12-08 |
Molecular Partners Ag |
Novel ankyrin repeat binding proteins and their uses
|
|
JP2023528204A
(ja)
|
2020-05-14 |
2023-07-04 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
多選択性タンパク質
|
|
EP4023218A1
(en)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Combination therapy for patients having acute and/or persistent dyspnea
|
|
US20240108746A1
(en)
|
2020-12-16 |
2024-04-04 |
Molecular Partners Ag |
Novel slow-release prodrugs
|
|
EP4305063A1
(en)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Protease cleavable prodrugs
|
|
WO2022190018A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
|
JP2024508969A
(ja)
|
2021-03-09 |
2024-02-28 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ
|
|
JP2024509904A
(ja)
|
2021-03-09 |
2024-03-05 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ
|
|
US12472148B2
(en)
|
2021-04-26 |
2025-11-18 |
Celanese Eva Performance Polymers Llc |
Implantable device for sustained release of a macromolecular drug compound
|
|
WO2022263648A1
(en)
|
2021-06-18 |
2022-12-22 |
Sphingotec Gmbh |
A method for predicting sepsis and septic shock
|
|
WO2023275099A1
(en)
|
2021-06-29 |
2023-01-05 |
Berysol Gmbh |
Composite biomarker for the identification of selenium deficiency in a bodily fluid
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
WO2023110983A1
(en)
|
2021-12-14 |
2023-06-22 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity and their use
|
|
JP2025509304A
(ja)
|
2022-03-15 |
2025-04-11 |
アドレノメト アクチェンゲゼルシャフト |
抗アドレノメデュリン（ａｄｍ）抗体又は抗ａｄｍ抗体フラグメントの安定な水性製剤
|
|
EP4562430A1
(en)
|
2022-07-29 |
2025-06-04 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
|
JP2025525059A
(ja)
|
2022-07-29 |
2025-08-01 |
アドレノメト アクチェンゲゼルシャフト |
ショックの治療又は予防に使用するための抗アドレノメデュリン（ＡＤＭ）抗体若しくは抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
|
|
CA3262553A1
(en)
|
2022-08-01 |
2024-02-08 |
Molecular Partners Ag |
REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE
|
|
WO2024038307A1
(en)
|
2022-08-19 |
2024-02-22 |
Novartis Ag |
Dosing regimens for sars-cov-2 binding molecules
|
|
WO2024059686A2
(en)
*
|
2022-09-15 |
2024-03-21 |
The Regents Of The University Of California |
Darpin backbones and rigidified electron microscopy imaging scaffolds
|
|
CN120359042A
(zh)
|
2022-12-15 |
2025-07-22 |
4Teen4制药有限公司 |
改善危重病患者肺功能的dpp3抑制剂
|
|
WO2024179981A1
(en)
|
2023-02-27 |
2024-09-06 |
Molecular Partners Ag |
Darpins for use in reducing renal accumulation of drugs
|
|
WO2024194276A1
(en)
|
2023-03-17 |
2024-09-26 |
Pam Theragnostics Gmbh |
Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
|
|
WO2024200862A1
(en)
|
2023-03-29 |
2024-10-03 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
|
|
WO2025068313A1
(en)
|
2023-09-25 |
2025-04-03 |
Sphingotec Gmbh |
A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
|
|
WO2025146491A1
(en)
|
2024-01-05 |
2025-07-10 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
|
|
WO2025229075A1
(en)
|
2024-05-03 |
2025-11-06 |
Sphingotec Gmbh |
A method for the specific determination of proenkephalin fragment 119-159
|
|
WO2025248139A1
(en)
|
2024-05-31 |
2025-12-04 |
4TEEN4 Pharmaceuticals GmbH |
Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
|